/
DCF Valuation
Base-case fair value
$80.58
Intrinsic $107.44 · 25% MOS
Current price: $3.07
Base-case summary
Our base-case DCF for Fortress Biotech, Inc. (FBIO) projects 10 years of free cash flow growth at 8.0% for years 1–5 and 4.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $158M in trailing free cash flow, this produces an intrinsic value of $107.44 per share. A 25% safety margin gives a fair value of $80.58, suggesting the stock is currently 2525% undervalued against the $3.07 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$158M
Cash & equivalents
$256M
Total debt
$54M
Shares outstanding
38M